Loading clinical trials...
Loading clinical trials...
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME)
Conditions
Interventions
KSI-301
Aflibercept
+1 more
Locations
72
United States
Retinal Research Institute, LLC
Phoenix, Arizona, United States
Retina Vitreous Associates
Beverly Hills, California, United States
Retina Consultants of Orange County
Fullerton, California, United States
Northern California Retina Vitreous Associates
Mountain View, California, United States
Retina Consultants of San Diego
Poway, California, United States
Retinal Consultants Medical Group Inc
Sacramento, California, United States
Start Date
September 30, 2020
Primary Completion Date
April 27, 2023
Completion Date
August 31, 2023
Last Updated
August 22, 2024
NCT07425522
NCT07308639
NCT07449936
NCT07449923
NCT06439576
NCT07228559
Lead Sponsor
Kodiak Sciences Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions